PVC Cheat Sheet 2026

The 30 highest-yield PVC facts, distilled from real exam questions. Print it, save it as a PDF, or study it here — free, no sign-up.

1. How does continuing education relate to quality assurance & continuous improvement for PVC certified professionals? → It ensures professionals stay current with evolving standards and best practices
2. When a conflict arises between standard procedures and a unique situation in Individual Case Safety Reports, what should a PVC professional prioritize? → Safety and ethical obligations while seeking expert consultation
3. Which of the following scenarios would NOT trigger an expedited 15-day safety report to the FDA for a marketed product? → A report from a post-marketing study showing a serious expected adverse reaction
4. According to ICH E2A, which of the following criteria is NOT required to classify an adverse event as a SUSAR? → The event must be fatal
5. Under 21 CFR 312.32, a sponsor must notify FDA of an IND safety report for an unexpected serious adverse reaction within what timeframe? → 15 calendar days
6. What is the significance of peer review in regulatory compliance & legal framework for PVC professionals? → It promotes accountability, knowledge sharing, and quality improvement
7. Which organization provides guidance on signal management in the EU? → EMA
8. Which metric in a disproportionality analysis indicates a statistically significant drug-event association when its lower 95% confidence interval exceeds 1.0? → Reporting Odds Ratio (ROR)
9. In MedDRA hierarchy, which level is most commonly used as the unit of analysis in disproportionality signal detection? → Preferred Term (PT)
10. In Pharmacovigilance Certification, what role does quality assurance & continuous improvement play in ensuring client/stakeholder satisfaction? → It builds trust through demonstrated competence and consistency
11. What is the key difference between a Type A and Type B adverse drug reaction? → Type A is dose-related and predictable; Type B is idiosyncratic and unpredictable
12. What is the PRIMARY purpose of continuing education requirements in Adverse Drug Reaction Reporting for PVC professionals? → Maintaining current knowledge and competency as the field evolves
13. When implementing regulatory compliance & legal framework practices, what should a PVC professional prioritize first? → Compliance with established standards and protocols
14. Which patient population factor most commonly shifts a benefit-risk balance from unfavorable to favorable for a high-risk drug? → Patients with severe, life-threatening disease with no adequate alternative therapy
15. What is the PRIMARY purpose of continuing education requirements in Signal Detection & Analysis for PVC professionals? → Maintaining current knowledge and competency as the field evolves
16. Which regulatory framework requires sponsors to submit Individual Case Safety Reports (ICSRs) for serious unexpected adverse events during clinical trials? → ICH E2A Clinical Safety Data Management
17. In quantitative signal detection, what does a 'shrinkage' method like the MGPS or BCPNN protect against? → Inflated disproportionality estimates from drug-event pairs with very few reports
18. A drug sponsor identifies a new safety signal in post-marketing data. What is the FIRST regulatory action typically required? → Evaluate the signal and report it to the FDA within required timeframes
19. In a benefit-risk assessment, the 'comparator' is most appropriately chosen as: → The current standard of care or best available therapy for the same indication
20. In pharmacovigilance benefit-risk assessment, 'uncertainty' refers primarily to: → Gaps or limitations in the available evidence about benefits or risks
21. Which document outlines the obligations of a Marketing Authorization Holder (MAH) in pharmacovigilance? → Risk Management Plan
22. In Adverse Drug Reaction Reporting, what is the FIRST step a PVC professional should take when encountering a new case or situation? → Conduct a comprehensive assessment and gather all relevant information
23. In the context of signal detection, what is the primary risk of using a very low minimum threshold (e.g., N≥1) for reporting count? → Excessive false-positive signals from sparse data instability
24. Which regulatory framework governs pharmacovigilance obligations for sponsors conducting clinical trials within the European Union? → EU Clinical Trials Regulation (EU) No 536/2014
25. When a company receives an ICSR from a patient support program it sponsors, how should the case be classified? → Solicited report
26. Under FDA regulations, what is the expedited reporting timeframe for a serious, unexpected, and drug-related adverse event from a clinical trial? → 15 calendar days
27. Which of the following represents best practice in medical coding quality review? → Ensure the selected PT accurately and specifically reflects the clinical concept described
28. When implementing professional standards & ethics practices, what should a PVC professional prioritize first? → Compliance with established standards and protocols
29. Which coding dictionary is the international standard for classifying adverse event terms in pharmacovigilance reporting? → MedDRA (Medical Dictionary for Regulatory Activities)
30. In the BRAT framework, what is the primary purpose of the 'value tree'? → To organize and categorize key benefit and risk outcomes